Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen
An over-active alternative complement pathway has been implicated in the pathophysiology of multiple diseases, including IgA nephropathy and geographic atrophy secondary to age related macular degeneration. In first-in-human double-blind, placebo-controlled phase 1 studies, the safety and pharmacody...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Immunobiology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0171298525000105 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832573193273999360 |
|---|---|
| author | Michael L. McCaleb Steven G. Hughes Tamar R. Grossman Ashley Frazer-Abel Bill Jung Lixuan Yin Scott P. Henry Brett P. Monia Eugene Schneider Richard Geary Gary T. Brice |
| author_facet | Michael L. McCaleb Steven G. Hughes Tamar R. Grossman Ashley Frazer-Abel Bill Jung Lixuan Yin Scott P. Henry Brett P. Monia Eugene Schneider Richard Geary Gary T. Brice |
| author_sort | Michael L. McCaleb |
| collection | DOAJ |
| description | An over-active alternative complement pathway has been implicated in the pathophysiology of multiple diseases, including IgA nephropathy and geographic atrophy secondary to age related macular degeneration. In first-in-human double-blind, placebo-controlled phase 1 studies, the safety and pharmacodynamic effects of sefaxersen (RO7434656), a GalNAc-conjugated 2’-MOE antisense oligonucleotide targeting the complement factor B mRNA, was investigated. Healthy volunteers received either single or repeated (for 6 weeks) subcutaneous administrations of investigational drug or placebo. Safety and plasma complement protein levels were assessed throughout the studies and during 90-day follow-up periods. All subjects (54) completed the studies and no safety signals or clinically meaningful changes in blood chemistry, urinalysis, hematology, ECG, vital signs or ocular endpoints were observed. Mean levels of systemic complement factor B (FB) were reduced up to 38 % after single administration and 69 % after repeated administration. Lowering of FB protein was paralleled by similar reductions of plasma Bb levels. There was a strong correlation between reduction of plasma levels of FB and alternative complement pathway activity (AH50), but no meaningful changes in classical complement pathway activity (CH50). The long duration of lowering of FB levels following the last dose supports monthly dosing in future clinical trials. These clinical results support the ongoing Phase 2 development for geographic atrophy secondary to age-related macular degeneration and Ph 2/3 development for IgA nephropathy. |
| format | Article |
| id | doaj-art-0f6a474776794e6093d8abac94e34310 |
| institution | Kabale University |
| issn | 0171-2985 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Immunobiology |
| spelling | doaj-art-0f6a474776794e6093d8abac94e343102025-02-02T05:26:40ZengElsevierImmunobiology0171-29852025-03-012302152876Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with SefaxersenMichael L. McCaleb0Steven G. Hughes1Tamar R. Grossman2Ashley Frazer-Abel3Bill Jung4Lixuan Yin5Scott P. Henry6Brett P. Monia7Eugene Schneider8Richard Geary9Gary T. Brice10Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USAIonis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USAIonis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USAExsera Biolabs, University of Colorado Denver, 1775 Aurora Ct., Aurora, CO 80045, USAIonis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USAIonis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USAIonis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USAIonis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USAIonis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USAIonis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USAIonis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USA; Corresponding author at: Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.An over-active alternative complement pathway has been implicated in the pathophysiology of multiple diseases, including IgA nephropathy and geographic atrophy secondary to age related macular degeneration. In first-in-human double-blind, placebo-controlled phase 1 studies, the safety and pharmacodynamic effects of sefaxersen (RO7434656), a GalNAc-conjugated 2’-MOE antisense oligonucleotide targeting the complement factor B mRNA, was investigated. Healthy volunteers received either single or repeated (for 6 weeks) subcutaneous administrations of investigational drug or placebo. Safety and plasma complement protein levels were assessed throughout the studies and during 90-day follow-up periods. All subjects (54) completed the studies and no safety signals or clinically meaningful changes in blood chemistry, urinalysis, hematology, ECG, vital signs or ocular endpoints were observed. Mean levels of systemic complement factor B (FB) were reduced up to 38 % after single administration and 69 % after repeated administration. Lowering of FB protein was paralleled by similar reductions of plasma Bb levels. There was a strong correlation between reduction of plasma levels of FB and alternative complement pathway activity (AH50), but no meaningful changes in classical complement pathway activity (CH50). The long duration of lowering of FB levels following the last dose supports monthly dosing in future clinical trials. These clinical results support the ongoing Phase 2 development for geographic atrophy secondary to age-related macular degeneration and Ph 2/3 development for IgA nephropathy.http://www.sciencedirect.com/science/article/pii/S0171298525000105Complement Alternative PathwayAntisense oligonucleotidesComplement factor BTherapeutics |
| spellingShingle | Michael L. McCaleb Steven G. Hughes Tamar R. Grossman Ashley Frazer-Abel Bill Jung Lixuan Yin Scott P. Henry Brett P. Monia Eugene Schneider Richard Geary Gary T. Brice Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen Immunobiology Complement Alternative Pathway Antisense oligonucleotides Complement factor B Therapeutics |
| title | Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen |
| title_full | Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen |
| title_fullStr | Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen |
| title_full_unstemmed | Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen |
| title_short | Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen |
| title_sort | inhibiting the alternative pathway of complement by reducing systemic complement factor b randomized double blind placebo controlled phase 1 studies with sefaxersen |
| topic | Complement Alternative Pathway Antisense oligonucleotides Complement factor B Therapeutics |
| url | http://www.sciencedirect.com/science/article/pii/S0171298525000105 |
| work_keys_str_mv | AT michaellmccaleb inhibitingthealternativepathwayofcomplementbyreducingsystemiccomplementfactorbrandomizeddoubleblindplacebocontrolledphase1studieswithsefaxersen AT stevenghughes inhibitingthealternativepathwayofcomplementbyreducingsystemiccomplementfactorbrandomizeddoubleblindplacebocontrolledphase1studieswithsefaxersen AT tamarrgrossman inhibitingthealternativepathwayofcomplementbyreducingsystemiccomplementfactorbrandomizeddoubleblindplacebocontrolledphase1studieswithsefaxersen AT ashleyfrazerabel inhibitingthealternativepathwayofcomplementbyreducingsystemiccomplementfactorbrandomizeddoubleblindplacebocontrolledphase1studieswithsefaxersen AT billjung inhibitingthealternativepathwayofcomplementbyreducingsystemiccomplementfactorbrandomizeddoubleblindplacebocontrolledphase1studieswithsefaxersen AT lixuanyin inhibitingthealternativepathwayofcomplementbyreducingsystemiccomplementfactorbrandomizeddoubleblindplacebocontrolledphase1studieswithsefaxersen AT scottphenry inhibitingthealternativepathwayofcomplementbyreducingsystemiccomplementfactorbrandomizeddoubleblindplacebocontrolledphase1studieswithsefaxersen AT brettpmonia inhibitingthealternativepathwayofcomplementbyreducingsystemiccomplementfactorbrandomizeddoubleblindplacebocontrolledphase1studieswithsefaxersen AT eugeneschneider inhibitingthealternativepathwayofcomplementbyreducingsystemiccomplementfactorbrandomizeddoubleblindplacebocontrolledphase1studieswithsefaxersen AT richardgeary inhibitingthealternativepathwayofcomplementbyreducingsystemiccomplementfactorbrandomizeddoubleblindplacebocontrolledphase1studieswithsefaxersen AT garytbrice inhibitingthealternativepathwayofcomplementbyreducingsystemiccomplementfactorbrandomizeddoubleblindplacebocontrolledphase1studieswithsefaxersen |